BRPI0718564A2

BRPI0718564A2 - Composto, métodos para preparar um composto, para gerar análogos de ansamicina, para tratar uma doença, e para produzir um composto, análogo de ansamicina, composição farmacêutica, uso de um análogo de ansamicina, cepa engenheirada, e, uso de uma cepa engenheirada.

Composto, métodos para preparar um composto, para gerar análogos de ansamicina, para tratar uma doença, e para produzir um composto, análogo de ansamicina, composição farmacêutica, uso de um análogo de ansamicina, cepa engenheirada, e, uso de uma cepa engenheirada. Download PDF

Info

Publication number: BRPI0718564A2
Authority: BR; Brazil
Prior art keywords: formula; strain; ansamycin; represent; gene
Prior art date: 2006-11-09

Application number

BRPI0718564-2A

Other languages

English (en)

Portuguese (pt)

Inventor

Christine Martin

Original Assignee

Biotica Tech Ltd

Priority date

2006-11-09

Filing date

2007-11-09

Publication date

2014-03-11

2006-11-09 Priority claimed from GBGB0622342.4A external-priority patent/GB0622342D0/en

2007-10-24 Priority claimed from GB0720875A external-priority patent/GB0720875D0/en

2007-11-09 Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd

2014-03-11 Publication of BRPI0718564A2 publication Critical patent/BRPI0718564A2/pt

Links

150000001875 compounds Chemical class 0.000 title claims description 154
238000000034 method Methods 0.000 title claims description 109
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 17
201000010099 disease Diseases 0.000 title claims description 15
ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical class CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 title 3
UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 title 1
238000004690 coupled electron pair approximation Methods 0.000 title 1
108090000623 proteins and genes Proteins 0.000 claims description 201
ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical class O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 claims description 134
QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims description 106
JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims description 100
QPEJHSFTZVMSJH-UHFFFAOYSA-N 3-amino-5-hydroxybenzoic acid Chemical compound NC1=CC(O)=CC(C(O)=O)=C1 QPEJHSFTZVMSJH-UHFFFAOYSA-N 0.000 claims description 81
229960000885 rifabutin Drugs 0.000 claims description 60
MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 claims description 54
206010028980 Neoplasm Diseases 0.000 claims description 41
229930193320 herbimycin Natural products 0.000 claims description 40
230000015572 biosynthetic process Effects 0.000 claims description 39
238000004519 manufacturing process Methods 0.000 claims description 39
229910052731 fluorine Inorganic materials 0.000 claims description 37
230000001851 biosynthetic effect Effects 0.000 claims description 33
239000003999 initiator Substances 0.000 claims description 33
229910052739 hydrogen Inorganic materials 0.000 claims description 32
150000003839 salts Chemical class 0.000 claims description 32
108020004414 DNA Proteins 0.000 claims description 31
239000007858 starting material Substances 0.000 claims description 31
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 29
201000011510 cancer Diseases 0.000 claims description 26
-1 prenisone Chemical compound 0.000 claims description 26
239000000203 mixture Substances 0.000 claims description 24
239000003814 drug Substances 0.000 claims description 23
239000002253 acid Substances 0.000 claims description 22
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 21
238000011282 treatment Methods 0.000 claims description 15
210000003719 b-lymphocyte Anatomy 0.000 claims description 13
230000001419 dependent effect Effects 0.000 claims description 13
230000036983 biotransformation Effects 0.000 claims description 12
230000036210 malignancy Effects 0.000 claims description 12
108020004635 Complementary DNA Proteins 0.000 claims description 11
102000053602 DNA Human genes 0.000 claims description 11
241000187391 Streptomyces hygroscopicus Species 0.000 claims description 11
238000010804 cDNA synthesis Methods 0.000 claims description 11
239000002299 complementary DNA Substances 0.000 claims description 11
208000023275 Autoimmune disease Diseases 0.000 claims description 9
241000187180 Streptomyces sp. Species 0.000 claims description 9
241000970854 Streptomyces violaceusniger Species 0.000 claims description 9
230000033115 angiogenesis Effects 0.000 claims description 9
208000015114 central nervous system disease Diseases 0.000 claims description 9
230000004770 neurodegeneration Effects 0.000 claims description 9
208000015122 neurodegenerative disease Diseases 0.000 claims description 9
206010017533 Fungal infection Diseases 0.000 claims description 8
208000031888 Mycoses Diseases 0.000 claims description 8
201000004792 malaria Diseases 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 8
239000003085 diluting agent Substances 0.000 claims description 7
238000010348 incorporation Methods 0.000 claims description 7
239000003112 inhibitor Substances 0.000 claims description 7
230000000069 prophylactic effect Effects 0.000 claims description 7
AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 claims description 6
125000001153 fluoro group Chemical group F* 0.000 claims description 6
230000000415 inactivating effect Effects 0.000 claims description 6
238000002203 pretreatment Methods 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
239000011737 fluorine Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
108010048784 3-amino-5-hydroxybenzoic acid synthase Proteins 0.000 claims description 4
102000007132 Carboxyl and Carbamoyl Transferases Human genes 0.000 claims description 4
108010072957 Carboxyl and Carbamoyl Transferases Proteins 0.000 claims description 4
102000003964 Histone deacetylase Human genes 0.000 claims description 4
108090000353 Histone deacetylase Proteins 0.000 claims description 4
102000008109 Mixed Function Oxygenases Human genes 0.000 claims description 4
108010074633 Mixed Function Oxygenases Proteins 0.000 claims description 4
108091000080 Phosphotransferase Proteins 0.000 claims description 4
241001655322 Streptomycetales Species 0.000 claims description 4
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
238000007385 chemical modification Methods 0.000 claims description 4
102000020233 phosphotransferase Human genes 0.000 claims description 4
UENRXLSRMCSUSN-UHFFFAOYSA-N 3,5-diaminobenzoic acid Chemical compound NC1=CC(N)=CC(C(O)=O)=C1 UENRXLSRMCSUSN-UHFFFAOYSA-N 0.000 claims description 3
BWKDAAFSXYPQOS-UHFFFAOYSA-N Benzaldehyde glyceryl acetal Chemical compound O1CC(O)COC1C1=CC=CC=C1 BWKDAAFSXYPQOS-UHFFFAOYSA-N 0.000 claims description 3
108090001042 Hydro-Lyases Proteins 0.000 claims description 3
102000004867 Hydro-Lyases Human genes 0.000 claims description 3
241000810757 Streptomyces geldanamycininus Species 0.000 claims description 3
150000001408 amides Chemical class 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
FXEMCOVVTSYFRJ-UHFFFAOYSA-N 3-amino-2,5,6-trifluorobenzoic acid Chemical compound NC1=CC(F)=C(F)C(C(O)=O)=C1F FXEMCOVVTSYFRJ-UHFFFAOYSA-N 0.000 claims description 2
DMGFVJVLVZOSOE-UHFFFAOYSA-N 3-amino-4-chlorobenzoic acid Chemical compound NC1=CC(C(O)=O)=CC=C1Cl DMGFVJVLVZOSOE-UHFFFAOYSA-N 0.000 claims description 2
RYLBYCHERDTVAY-UHFFFAOYSA-N 3-amino-5-fluorobenzoic acid Chemical compound NC1=CC(F)=CC(C(O)=O)=C1 RYLBYCHERDTVAY-UHFFFAOYSA-N 0.000 claims description 2
YQXQZKKJAITNKW-UHFFFAOYSA-N 5-amino-2,3-difluorobenzoic acid Chemical compound NC1=CC(F)=C(F)C(C(O)=O)=C1 YQXQZKKJAITNKW-UHFFFAOYSA-N 0.000 claims description 2
WYGAIOJWQDRBRJ-UHFFFAOYSA-N 5-amino-2-fluorobenzoic acid Chemical compound NC1=CC=C(F)C(C(O)=O)=C1 WYGAIOJWQDRBRJ-UHFFFAOYSA-N 0.000 claims description 2
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 2
MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
108010006654 Bleomycin Proteins 0.000 claims description 2
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 2
108010069236 Goserelin Proteins 0.000 claims description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 2
239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
102000004316 Oxidoreductases Human genes 0.000 claims description 2
108090000854 Oxidoreductases Proteins 0.000 claims description 2
229930012538 Paclitaxel Natural products 0.000 claims description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 2
229940123237 Taxane Drugs 0.000 claims description 2
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 2
229960002932 anastrozole Drugs 0.000 claims description 2
239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
229940121369 angiogenesis inhibitor Drugs 0.000 claims description 2
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 claims description 2
229960000397 bevacizumab Drugs 0.000 claims description 2
229960001561 bleomycin Drugs 0.000 claims description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
229960001467 bortezomib Drugs 0.000 claims description 2
229960004117 capecitabine Drugs 0.000 claims description 2
229960005395 cetuximab Drugs 0.000 claims description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
229960004316 cisplatin Drugs 0.000 claims description 2
229960004397 cyclophosphamide Drugs 0.000 claims description 2
229960000684 cytarabine Drugs 0.000 claims description 2
229960002448 dasatinib Drugs 0.000 claims description 2
230000007423 decrease Effects 0.000 claims description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 2
229960003668 docetaxel Drugs 0.000 claims description 2
229960001433 erlotinib Drugs 0.000 claims description 2
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
229960002949 fluorouracil Drugs 0.000 claims description 2
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 2
235000008191 folinic acid Nutrition 0.000 claims description 2
239000011672 folinic acid Substances 0.000 claims description 2
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
229960002584 gefitinib Drugs 0.000 claims description 2
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
229960005277 gemcitabine Drugs 0.000 claims description 2
229960002913 goserelin Drugs 0.000 claims description 2
238000001794 hormone therapy Methods 0.000 claims description 2
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
229960002411 imatinib Drugs 0.000 claims description 2
229960004891 lapatinib Drugs 0.000 claims description 2
BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 2
GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 2
229960004942 lenalidomide Drugs 0.000 claims description 2
229960001691 leucovorin Drugs 0.000 claims description 2
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 2
229960004296 megestrol acetate Drugs 0.000 claims description 2
229960000485 methotrexate Drugs 0.000 claims description 2
238000002625 monoclonal antibody therapy Methods 0.000 claims description 2
229960001592 paclitaxel Drugs 0.000 claims description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
239000003909 protein kinase inhibitor Substances 0.000 claims description 2
238000001959 radiotherapy Methods 0.000 claims description 2
229960003787 sorafenib Drugs 0.000 claims description 2
229960001796 sunitinib Drugs 0.000 claims description 2
WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
238000001356 surgical procedure Methods 0.000 claims description 2
229960001603 tamoxifen Drugs 0.000 claims description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
229960000235 temsirolimus Drugs 0.000 claims description 2
QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 2
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 2
229960005026 toremifene Drugs 0.000 claims description 2
229960000575 trastuzumab Drugs 0.000 claims description 2
229960003048 vinblastine Drugs 0.000 claims description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
229960004528 vincristine Drugs 0.000 claims description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
229960002066 vinorelbine Drugs 0.000 claims description 2
WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 2
229960000237 vorinostat Drugs 0.000 claims description 2
101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 claims 1
101001128634 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Proteins 0.000 claims 1
102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 claims 1
PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 claims 1
102100032194 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Human genes 0.000 claims 1
101710100170 Unknown protein Proteins 0.000 claims 1
WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims 1
230000004853 protein function Effects 0.000 claims 1
239000012634 fragment Substances 0.000 description 31
210000004027 cell Anatomy 0.000 description 30
241000187747 Streptomyces Species 0.000 description 27
239000002609 medium Substances 0.000 description 24
238000012217 deletion Methods 0.000 description 23
230000037430 deletion Effects 0.000 description 23
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 21
102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 19
101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
230000000694 effects Effects 0.000 description 17
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 17
239000004480 active ingredient Substances 0.000 description 16
239000013612 plasmid Substances 0.000 description 16
230000027455 binding Effects 0.000 description 14
235000018102 proteins Nutrition 0.000 description 14
102000004169 proteins and genes Human genes 0.000 description 14
MCAHMSDENAOJFZ-UHFFFAOYSA-N Herbimycin A Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-UHFFFAOYSA-N 0.000 description 13
102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 13
XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 description 13
229950006334 apramycin Drugs 0.000 description 13
239000000047 product Substances 0.000 description 13
VFJOOSVDHSUNKR-DQJDZTSCSA-N [(3r,5s,6r,7s,8e,10s,11s,14e)-6,20-dihydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16-oxo-17-azabicyclo[16.3.1]docosa-1(22),8,14,18,20-pentaen-10-yl] carbamate Chemical class C1[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)\C=C(C)\[C@H](OC(N)=O)[C@@H](OC)CC\C=C(C)\C(=O)NC2=CC(O)=C(OC)C1=C2 VFJOOSVDHSUNKR-DQJDZTSCSA-N 0.000 description 11
230000002779 inactivation Effects 0.000 description 11
229930001119 polyketide Natural products 0.000 description 11
108091034117 Oligonucleotide Proteins 0.000 description 10
230000006870 function Effects 0.000 description 10
108091008053 gene clusters Proteins 0.000 description 10
239000000523 sample Substances 0.000 description 10
241000143227 Actinosynnema pretiosum Species 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
LVOKZOGSKLUKGN-UHFFFAOYSA-N Herbimycin B Natural products COC1CC(C)C(O)C2=CC(=O)C=C(NC(=O)C(=CC=C/C(OC)C(OC(=O)N)C(=CC(C)C1O)C)C)C2=O LVOKZOGSKLUKGN-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
101150059547 PRKCI gene Proteins 0.000 description 9
DWFFHRSGCPBMKD-OZVZJJIRSA-N [(2r,3s,5r,6s,7r,8e,10r,11r,12z,14e)-6-hydroxy-2,5,11-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C/[C@@H](OC)[C@H](OC(N)=O)\C(C)=C\[C@@H](C)[C@H](O)[C@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O DWFFHRSGCPBMKD-OZVZJJIRSA-N 0.000 description 9
ZRACUXWBSYZVLW-LCXCNHHZSA-N [(3r,5s,6r,7s,8e,10s,11s,12z,14e)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=CC(=O)C=C1C2=O ZRACUXWBSYZVLW-LCXCNHHZSA-N 0.000 description 9
VFJOOSVDHSUNKR-UHFFFAOYSA-N reblastatin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(O)=C(OC)C1=C2 VFJOOSVDHSUNKR-UHFFFAOYSA-N 0.000 description 9
238000010561 standard procedure Methods 0.000 description 9
241000123665 Actinosynnema mirum Species 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 8
229940079593 drug Drugs 0.000 description 8
238000009472 formulation Methods 0.000 description 8
239000003481 heat shock protein 90 inhibitor Substances 0.000 description 8
239000000543 intermediate Substances 0.000 description 8
239000007788 liquid Substances 0.000 description 8
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
HUXWGTSMSXMDBH-UHFFFAOYSA-N progeldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(O)=CC1=C2 HUXWGTSMSXMDBH-UHFFFAOYSA-N 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
230000021615 conjugation Effects 0.000 description 7
239000000725 suspension Substances 0.000 description 7
239000013598 vector Substances 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000010367 cloning Methods 0.000 description 6
230000012010 growth Effects 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
238000012986 modification Methods 0.000 description 6
230000004048 modification Effects 0.000 description 6
MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 6
229960000210 nalidixic acid Drugs 0.000 description 6
239000002674 ointment Substances 0.000 description 6
239000000843 powder Substances 0.000 description 6
238000012552 review Methods 0.000 description 6
238000012163 sequencing technique Methods 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
150000001558 benzoic acid derivatives Chemical class 0.000 description 5
230000003115 biocidal effect Effects 0.000 description 5
235000010633 broth Nutrition 0.000 description 5
229940041514 candida albicans extract Drugs 0.000 description 5
239000000969 carrier Substances 0.000 description 5
210000000349 chromosome Anatomy 0.000 description 5
239000000284 extract Substances 0.000 description 5
238000007429 general method Methods 0.000 description 5
150000003881 polyketide derivatives Chemical class 0.000 description 5
239000013587 production medium Substances 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
239000003826 tablet Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
239000012138 yeast extract Substances 0.000 description 5
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
241001478513 Actinosynnema pretiosum subsp. pretiosum Species 0.000 description 4
229920001817 Agar Polymers 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
101710116650 FAD-dependent monooxygenase Proteins 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
206010019851 Hepatotoxicity Diseases 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
101710128228 O-methyltransferase Proteins 0.000 description 4
239000001888 Peptone Substances 0.000 description 4
108010080698 Peptones Proteins 0.000 description 4
JUHXUUXMSBXUJZ-ISVCGJASSA-N Progeldanamycin Chemical compound C1[C@@H](C)C[C@H](OC)[C@H](O)C(C)\C=C(C)\[C@H](O)[C@@H](OC)CC\C=C(C)\C(=O)NC2=CC(O)=CC1=C2 JUHXUUXMSBXUJZ-ISVCGJASSA-N 0.000 description 4
238000002105 Southern blotting Methods 0.000 description 4
241000187759 Streptomyces albus Species 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
239000013543 active substance Substances 0.000 description 4
239000008272 agar Substances 0.000 description 4
239000006071 cream Substances 0.000 description 4
238000012377 drug delivery Methods 0.000 description 4
238000001976 enzyme digestion Methods 0.000 description 4
238000000855 fermentation Methods 0.000 description 4
230000004151 fermentation Effects 0.000 description 4
235000019253 formic acid Nutrition 0.000 description 4
239000008103 glucose Substances 0.000 description 4
230000007686 hepatotoxicity Effects 0.000 description 4
231100000304 hepatotoxicity Toxicity 0.000 description 4
238000002744 homologous recombination Methods 0.000 description 4
230000006801 homologous recombination Effects 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
230000010354 integration Effects 0.000 description 4
235000013379 molasses Nutrition 0.000 description 4
235000019319 peptone Nutrition 0.000 description 4
230000005855 radiation Effects 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
238000011218 seed culture Methods 0.000 description 4
230000028070 sporulation Effects 0.000 description 4
239000000758 substrate Substances 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 4
229950007866 tanespimycin Drugs 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
239000012137 tryptone Substances 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
235000010643 Leucaena leucocephala Nutrition 0.000 description 3
240000007472 Leucaena leucocephala Species 0.000 description 3
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
230000001093 anti-cancer Effects 0.000 description 3
230000000843 anti-fungal effect Effects 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
238000013461 design Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000003120 macrolide antibiotic agent Chemical class 0.000 description 3
239000000463 material Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical class [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000002741 site-directed mutagenesis Methods 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229940032147 starch Drugs 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
230000001954 sterilising effect Effects 0.000 description 3
238000004659 sterilization and disinfection Methods 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000012546 transfer Methods 0.000 description 3
230000009466 transformation Effects 0.000 description 3
241000187712 Actinoplanes sp. Species 0.000 description 2
108700016155 Acyl transferases Proteins 0.000 description 2
102000057234 Acyl transferases Human genes 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
241001468213 Amycolatopsis mediterranei Species 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
235000016068 Berberis vulgaris Nutrition 0.000 description 2
241000335053 Beta vulgaris Species 0.000 description 2
241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
101710088194 Dehydrogenase Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical group OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
241000315040 Omura Species 0.000 description 2
102000004020 Oxygenases Human genes 0.000 description 2
108090000417 Oxygenases Proteins 0.000 description 2
102000055026 Protein O-Methyltransferase Human genes 0.000 description 2
108700040119 Protein O-Methyltransferase Proteins 0.000 description 2
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
229930189077 Rifamycin Natural products 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
241000187559 Saccharopolyspora erythraea Species 0.000 description 2
241000187432 Streptomyces coelicolor Species 0.000 description 2
241000187438 Streptomyces fradiae Species 0.000 description 2
241000187398 Streptomyces lividans Species 0.000 description 2
241001647839 Streptomyces tsukubensis Species 0.000 description 2
235000021536 Sugar beet Nutrition 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
240000008042 Zea mays Species 0.000 description 2
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
235000002017 Zea mays subsp mays Nutrition 0.000 description 2
KUFRQPKVAWMTJO-LMZWQJSESA-N alvespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-LMZWQJSESA-N 0.000 description 2
230000001772 anti-angiogenic effect Effects 0.000 description 2
230000000842 anti-protozoal effect Effects 0.000 description 2
239000003904 antiprotozoal agent Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
235000010216 calcium carbonate Nutrition 0.000 description 2
239000002775 capsule Substances 0.000 description 2
IOMXCGDXEUDZAK-UHFFFAOYSA-N chembl1511179 Chemical group OC1=CC=C2C=CC=CC2=C1N=NC1=NC=CS1 IOMXCGDXEUDZAK-UHFFFAOYSA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000004040 coloring Methods 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
235000005822 corn Nutrition 0.000 description 2
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical class C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
125000004494 ethyl ester group Chemical group 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
229960002989 glutamic acid Drugs 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
229940071676 hydroxypropylcellulose Drugs 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000002372 labelling Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 2
238000000465 moulding Methods 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
239000003921 oil Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000006072 paste Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
125000000830 polyketide group Chemical group 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
229930192524 radicicol Natural products 0.000 description 2
AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 2
229960003292 rifamycin Drugs 0.000 description 2
238000012216 screening Methods 0.000 description 2
229930000044 secondary metabolite Natural products 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
YVOFSHPIJOYKSH-NLYBMVFSSA-M sodium rifomycin sv Chemical compound [Na+].OC1=C(C(O)=C2C)C3=C([O-])C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O YVOFSHPIJOYKSH-NLYBMVFSSA-M 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
208000002320 spinal muscular atrophy Diseases 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
239000011573 trace mineral Substances 0.000 description 2
235000013619 trace mineral Nutrition 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
150000004057 1,4-benzoquinones Chemical class 0.000 description 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
VDNKJMUNLKAGAM-UHFFFAOYSA-N 1-pyridin-3-ylpropan-1-one Chemical compound CCC(=O)C1=CC=CN=C1 VDNKJMUNLKAGAM-UHFFFAOYSA-N 0.000 description 1
101150000874 11 gene Proteins 0.000 description 1
125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
HHCQVBCBDZQDKS-UHFFFAOYSA-N 8-Desmethylgeldanamycin Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C=CC(C)C(O)C(OC)CC(C)CC2=C(OC)C(=O)C=C1C2=O HHCQVBCBDZQDKS-UHFFFAOYSA-N 0.000 description 1
101710146995 Acyl carrier protein Proteins 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
QANBQEQVJJKJTJ-UHFFFAOYSA-N Antibiotic TAN 420E Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(O)=CC1=C2O QANBQEQVJJKJTJ-UHFFFAOYSA-N 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
241000599985 Beijerinckia mobilis Species 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
108091007914 CDKs Proteins 0.000 description 1
101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
101710134389 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2 Proteins 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
241000207199 Citrus Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
AFFSZNHAULCEKY-WBYSVDBMSA-N Geldanamycin Analog Chemical compound N1C(=O)\C(C)=C/C=C/C(OC)C(OC(N)=O)\C(C)=C\C(C)C(O)C(OC)CC(C)CC2=C(O)C1=CC(=O)C2=O AFFSZNHAULCEKY-WBYSVDBMSA-N 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
101001045218 Homo sapiens Peroxisomal multifunctional enzyme type 2 Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000908271 Ilyonectria destructans Species 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000012330 Integrases Human genes 0.000 description 1
108010061833 Integrases Proteins 0.000 description 1
239000005569 Iron sulphate Substances 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
208000008342 Leukemia P388 Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108060004795 Methyltransferase Proteins 0.000 description 1
102000016397 Methyltransferase Human genes 0.000 description 1
229940123379 Methyltransferase inhibitor Drugs 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241001134671 Micromonospora griseorubida Species 0.000 description 1
241000187723 Micromonospora sp. Species 0.000 description 1
108010006519 Molecular Chaperones Proteins 0.000 description 1
102000005431 Molecular Chaperones Human genes 0.000 description 1
101001014220 Monascus pilosus Dehydrogenase mokE Proteins 0.000 description 1
108010093369 Multienzyme Complexes Proteins 0.000 description 1
102000002568 Multienzyme Complexes Human genes 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
101710198130 NADPH-cytochrome P450 reductase Proteins 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
241000187654 Nocardia Species 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
101000573542 Penicillium citrinum Compactin nonaketide synthase, enoyl reductase component Proteins 0.000 description 1
102100022587 Peroxisomal multifunctional enzyme type 2 Human genes 0.000 description 1
108010002747 Pfu DNA polymerase Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
108010030975 Polyketide Synthases Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
208000024777 Prion disease Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000055027 Protein Methyltransferases Human genes 0.000 description 1
108700040121 Protein Methyltransferases Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
108010085012 Steroid Receptors Proteins 0.000 description 1
102000007451 Steroid Receptors Human genes 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241001276372 Streptomyces autolyticus Species 0.000 description 1
241001468227 Streptomyces avermitilis Species 0.000 description 1
241001312733 Streptomyces griseofuscus Species 0.000 description 1
241000810816 Streptomyces hygroscopicus subsp. duamyceticus Species 0.000 description 1
241000187419 Streptomyces rimosus Species 0.000 description 1
241000531819 Streptomyces venezuelae Species 0.000 description 1
241000287786 Streptomyces virus phiBT1 Species 0.000 description 1
241000701955 Streptomyces virus phiC31 Species 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
102100036236 Synaptonemal complex protein 2 Human genes 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
PVNFMCBFDPTNQI-UIBOPQHZSA-N [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] acetate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 3-methylbutanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] propanoate Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(C)=O)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CCC(=O)O[C@H]1CC(=O)N(C)c2cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@H](OC(=O)N3)[C@@H](C)C3O[C@@]13C)cc(OC)c2Cl.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)CC(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 PVNFMCBFDPTNQI-UIBOPQHZSA-N 0.000 description 1
XYFFWTYOFPSZRM-NBTLBREFSA-N [(3r,5r,6s,7r,8e,10r,11r,12z,14e)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical class N1C(=O)\C(C)=C\C=C/[C@@H](OC)[C@H](OC(N)=O)\C(C)=C\[C@@H](C)[C@H](O)[C@H](OC)C[C@H](C)CC2=C(N)C(=O)C=C1C2=O XYFFWTYOFPSZRM-NBTLBREFSA-N 0.000 description 1
QCXSABHHRSWSID-OOJAHTAHSA-N [(4e,6z,8s,9s,10e,12s,13r,14s,16s,17r)-13,20,22-trihydroxy-8,14,17-trimethoxy-4,10,12,16-tetramethyl-3-oxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19-hexaen-9-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(O)=CC1=C2O QCXSABHHRSWSID-OOJAHTAHSA-N 0.000 description 1
QANBQEQVJJKJTJ-BVXDHVRPSA-N [(4e,6z,8s,9s,10e,12s,13r,14s,16s,17r)-20,22-dihydroxy-8,13,14,17-tetramethoxy-4,10,12,16-tetramethyl-3-oxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19-hexaen-9-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(O)=CC1=C2O QANBQEQVJJKJTJ-BVXDHVRPSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000011949 advanced processing technology Methods 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
206010064930 age-related macular degeneration Diseases 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000003708 ampul Substances 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
238000002841 anti-cancer assay Methods 0.000 description 1
230000000078 anti-malarial effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
230000009876 antimalignant effect Effects 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000003491 array Methods 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
229940000031 blood and blood forming organ drug Drugs 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000005983 bone marrow dysfunction Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
235000020971 citrus fruits Nutrition 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000005100 correlation spectroscopy Methods 0.000 description 1
229960000956 coumarin Drugs 0.000 description 1
235000001671 coumarin Nutrition 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000003831 deregulation Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
238000010410 dusting Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012526 feed medium Substances 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000023611 glucuronidation Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
229940049654 glyceryl behenate Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
208000035474 group of disease Diseases 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
230000002363 herbicidal effect Effects 0.000 description 1
238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000012188 high-throughput screening assay Methods 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
239000008309 hydrophilic cream Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000007689 inspection Methods 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000008308 lipophilic cream Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
201000006512 mast cell neoplasm Diseases 0.000 description 1
208000006971 mastocytoma Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
239000003697 methyltransferase inhibitor Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
WYZWZEOGROVVHK-JVLMNHKTSA-N monorden Chemical compound C/1=C/C=C\C(=O)CC2=C(Cl)C(O)=CC(O)=C2C(=O)OC(C)CC2OC2\1 WYZWZEOGROVVHK-JVLMNHKTSA-N 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
231100000707 mutagenic chemical Toxicity 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000009520 phase I clinical trial Methods 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
239000011505 plaster Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
229910052939 potassium sulfate Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003217 pyrazoles Chemical class 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000003938 response to stress Effects 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
238000007789 sealing Methods 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000002356 single layer Substances 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
239000002689 soil Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
101150041594 soti gene Proteins 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000010257 thawing Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940100611 topical cream Drugs 0.000 description 1
229940100615 topical ointment Drugs 0.000 description 1
231100000440 toxicity profile Toxicity 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1
241001446247 uncultured actinomycete Species 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1